Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma [0.03%]
Pembrolizumab引起的长期不良事件：转移性黑色素瘤患者的炎性眼眶病
Charlée Nardin,Sophie Borot,Marie-Astride Beaudoin et al.
Charlée Nardin et al.
The recent advent of immune checkpoint inhibitors (ICI), including anti-programmed cell death 1 protein (anti-PD-1) agents has revolutionized the therapeutic approach of metastatic malignancies. Yet, ICI can disrupt immune tolerance resulti...
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma [0.03%]
一项I期研究：SGN-CD70A治疗CD70阳性弥漫性大B细胞淋巴瘤和套细胞淋巴瘤患者的疗效
Tycel Phillips,Paul M Barr,Steven I Park et al.
Tycel Phillips et al.
Purpose This first-in-human study evaluated SGN-CD70A, an antibody-drug conjugate (ADC) directed against the integral plasma membrane protein CD70 and linked to a pyrrolobenzodiazepine (PBD) dimer, in patients with relapsed or refractory (R...
Clinical Trial
Investigational new drugs. 2019 Apr;37(2):297-306. DOI:10.1007/s10637-018-0655-0 2019
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer [0.03%]
斯鲁安特联合紫杉醇一线治疗老年晚期非小细胞肺癌患者的Ⅰ期临床研究
Yusuke Chihara,Koji Date,Yoshizumi Takemura et al.
Yusuke Chihara et al.
This phase I study was aimed at determining the maximum tolerated dose (MTD) and recommended dose (RD) for oral S-1 plus paclitaxel combination therapy in elderly patients with non-small cell lung cancer (NSCLC). Chemotherapy-naïve patient...
Clinical Trial
Investigational new drugs. 2019 Apr;37(2):291-296. DOI:10.1007/s10637-018-0656-z 2019
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma [0.03%]
一项1期剂量递增研究：Millocitinib（一种 janus 激酶 1/2 抑制剂）联合吉西他滨和白蛋白结合型紫杉醇治疗既往未经治疗的转移性胰腺导管腺癌患者
Kimmie Ng,Andrew Hendifar,Alexander Starodub et al.
Kimmie Ng et al.
Purpose Preclinical evidence suggests the importance of Janus activating kinase (JAK) and TANK-binding kinase 1 (TBK1) in pancreatic ductal adenocarcinoma (PDAC). We evaluated the safety and efficacy of momelotinib (MMB), a JAK1/2 inhibitor...
Clinical Trial
Investigational new drugs. 2019 Feb;37(1):159-165. DOI:10.1007/s10637-018-0650-5 2019
The Monocarboxylate transporter inhibitor Quercetin induces intracellular acidification in a mouse model of Glioblastoma Multiforme: in-vivo detection using magnetic resonance imaging [0.03%]
利用磁共振成像对胶质母细胞瘤小鼠模型中檞皮素诱导的细胞内酸化进行体内检测
Mohammed Albatany,Susan Meakin,Robert Bartha
Mohammed Albatany
The response of tumor intracellular pH to a pharmacological challenge could help identify aggressive cancer. Chemical exchange saturation transfer (CEST) is an MRI contrast mechanism that is dependent on intracellular pH (pHi). pHi is impor...
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor [0.03%]
一项BGJ398(泛FGFR激酶抑制剂)与伊马替尼联合治疗晚期胃肠道间质瘤患者的Ⅰb期研究
Ciara M Kelly,Alexander N Shoushtari,Li-Xuan Qin et al.
Ciara M Kelly et al.
Background Preclinical studies suggest that imatinib resistance in gastrointestinal stromal tumor (GIST) can be mediated by MAP-kinase activation via fibroblast growth factor (FGF) signaling. In FGF stimulated GIST cell lines, BGJ398, a pan...
Clinical Trial
Investigational new drugs. 2019 Apr;37(2):282-290. DOI:10.1007/s10637-018-0648-z 2019
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) [0.03%]
tifanitinib治疗无症状或轻微转移性去势抵抗性前列腺癌的II期随机、双盲、安慰剂对照研究
Paul Monk,Glenn Liu,Walter M Stadler et al.
Paul Monk et al.
Background Tivantinib is a non-ATP competitive inhibitor of c-MET receptor tyrosine kinase that may have additional cytotoxic mechanisms including tubulin inhibition. Prostate cancer demonstrates higher c-MET expression as the disease progr...
Clinical Trial
Investigational new drugs. 2018 Oct;36(5):919-926. DOI:10.1007/s10637-018-0630-9 2018
Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015 [0.03%]
1991年至2015年肿瘤I期临床试验受试者中各类癌症分布的全球趋势变化分析
Kota Itahashi,Toshio Shimizu,Takafumi Koyama et al.
Kota Itahashi et al.
Background Systematic analyses regarding cancer types of patients enrolled in oncology phase I trials are scarce. The global distribution, time-dependent change, and regional differences were evaluated. Methods A systematic search of the Pu...
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer [0.03%]
尼克地尔在去势抵抗性前列腺癌中的研究进展及应用前景
Navid Sobhani,Daniele Generali,Alberto D&#x;Angelo et al.
Navid Sobhani et al.
Castrate-Resistant Prostate-Cancer (CRPC) is one of the most common malignancies occurring in men. Unfortunately, even if several recently approved agents clinically improved the outcome of CRPC patients, none of these is curative especiall...
Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma [0.03%]
非编码RNA在骨肉瘤发生发展、诊断和预后中的作用研究进展
Chongchong Wang,Juehua Jing,Li Cheng
Chongchong Wang
Non-coding RNAs (ncRNAs) have been found to play essential roles in various physiological and pathological processes. The involvement of ncRNAs in the development of osteosarcoma (OS) has been explored in recent years. In this review, we su...